These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29714543)

  • 1. Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility.
    Buhr KA; Downs M; Rhorer J; Bechhofer R; Wittes J
    Ther Innov Regul Sci; 2018 Jul; 52(4):459-468. PubMed ID: 29714543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance and role of independent data monitoring committees (IDMCs) in oncology clinical trials.
    Schöffski P
    BMJ Open; 2021 Oct; 11(10):e047294. PubMed ID: 34697110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On independent data monitoring committees in oncology clinical trials.
    Wittes J; Schactman M
    Chin Clin Oncol; 2014 Sep; 3(3):40. PubMed ID: 25841466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent data monitoring committees: preparing a path for the future.
    Hess CN; Roe MT; Gibson CM; Temple RJ; Pencina MJ; Zarin DA; Anstrom KJ; Alexander JH; Sherman RE; Fiedorek FT; Mahaffey KW; Lee KL; Chow SC; Armstrong PW; Califf RM
    Am Heart J; 2014 Aug; 168(2):135-41.e1. PubMed ID: 25066551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.
    Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL
    J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintaining confidentiality of interim data to enhance trial integrity and credibility.
    Fleming TR; Sharples K; McCall J; Moore A; Rodgers A; Stewart R
    Clin Trials; 2008; 5(2):157-67. PubMed ID: 18375654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review.
    Gewandter JS; Kitt RA; Hunsinger MR; Poku J; Lozano J; Chaudari J; Evans S; Gross RA; McDermott MP; Rowbotham MC; Turk DC; Dworkin RH
    J Clin Epidemiol; 2017 Mar; 83():101-107. PubMed ID: 28126598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protecting the confidentiality of interim data: addressing current challenges.
    Fleming TR
    Clin Trials; 2015 Feb; 12(1):5-11. PubMed ID: 25475877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent data monitoring committees: an update and overview.
    Sartor O; Halabi S
    Urol Oncol; 2015 Mar; 33(3):143-8. PubMed ID: 25631301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data and safety monitoring during randomized controlled trials of nursing interventions.
    Artinian NT; Froelicher ES; Vander Wal JS
    Nurs Res; 2004; 53(6):414-8. PubMed ID: 15586138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
    Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
    Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When enough is enough: how the decision was made to stop the FEAST trial: data and safety monitoring in an African trial of Fluid Expansion As Supportive Therapy (FEAST) for critically ill children.
    Todd J; Heyderman RS; Musoke P; Peto T
    Trials; 2013 Mar; 14():85. PubMed ID: 23531379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.